<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The <a href="https://www.researchandmarkets.com/reports/5749416/non-viral-transfection-reagents-market-3rd?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=32m7c6&amp;utm_campaign=2324451+-+Non-Viral+Transfection+Reagents+Market+Report+(3rd+Edition)+by+Type+of+Non-Viral+Transfection+Method%2c+Application+Area%2c+End-User+%26+Region%2c+Featuring+Bio-Rad%2c+MaxCyte%2c+MilliporeSigma%2c+Thermo+Fisher+Scientific&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035">"Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035"</a> has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market is projected to increase from USD 0.89 billion in 2026 to USD 2.01 billion by 2035, expanding at a compound annual growth rate of 9.5% during the forecast period. Market growth is being driven by rising demand for nucleic acid-based therapeutics, continued investment in cell and gene therapy research, and technological advances in intracellular delivery systems. Non-Viral Transfection Reagents Market Growth and Trends The expanding development and commercialization of gene therapies, mRNA therapeutics, RNA interference drugs, DNA vaccines, and gene-editing technologies are increasing demand for efficient transfection reagents and systems. Regulatory approvals for nucleic acid-based therapies have further reinforced the clinical and commercial potential of this therapeutic class. Industry stakeholders are increasingly adopting non-viral gene delivery technologies in response to the limitations associated with viral vectors, including immunogenicity, cytotoxicity, high manufacturing costs, restricted cargo capacity, and complex production requirements. Non-viral transfection platforms can offer greater scalability, manufacturing flexibility, and suitability for research and therapeutic workflows. Advances in lipid-based, polymer-based, nanoparticle-based, and electroporation systems are improving intracellular uptake, delivery precision, cell viability, and compatibility across diverse cell types. Nanotechnology-enabled carriers are also supporting targeted delivery through multifunctional designs that incorporate therapeutic payloads and targeting ligands. Products leveraging these technologies include jetOPTIMUS and PolyMag. Key Market Drivers and Challenges Major growth drivers include the increasing prevalence of chronic diseases, expanding pharmaceutical and biotechnology research expenditure, growing adoption of CRISPR-Cas9 and other gene-editing platforms, and rising demand for advanced cell and gene therapies. The need for scalable delivery technologies across research, process development, and clinical manufacturing is expected to create additional opportunities for non-viral transfection reagent developers. Despite a favorable outlook, the market faces challenges related to transfection efficiency in primary and hard-to-transfect cells. Limited intracellular uptake, genetic material stability, transient gene expression, reagent-related cytotoxicity, and variable performance across cell lines may also affect adoption. Additional barriers include the absence of standardized protocols, substantial optimization costs, regulatory complexity, and competition from emerging delivery platforms. Market Segmentation Highlights The non-viral transfection reagents market is segmented by transfection method, application, end-user, and geography. <ul><li>Method: Chemical methods, physical methods, and other methods</li><li>Application: Research applications and clinical applications</li><li>End-user: Academic and research institutions, pharmaceutical and biotechnology companies, contract manufacturers, and other end-users</li><li>Geography: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa</li></ul> Chemical methods account for nearly 60% of the overall non-viral transfection reagents and equipment market. This position is supported by the broad adoption of chemical reagents and non-viral vectors in primary cell transfection and gene therapy research. Physical methods are expected to register a comparatively higher growth rate through 2035, supported by advances in electroporation technologies that can provide shorter processing times, lower toxicity, and broad compatibility with nucleic acids and cell types. Research applications currently represent the largest market segment, reflecting extensive use across molecular biology, cell biology, drug discovery, and gene therapy development. Clinical applications are anticipated to expand at a faster rate as the number of approved and investigational cell and gene therapies continues to rise. Regional Non-Viral Transfection Reagents Market Outlook North America holds approximately 60% of the global market, supported by its established pharmaceutical and biotechnology sector, significant research funding, and concentration of companies developing complex biologics and advanced therapies. Demand is also strengthened by specialized handling requirements and the limited shelf life of certain transfection products, which can favor regional manufacturing and supply capabilities. The United States remains a major contributor to regional growth. Clear regulatory guidance from the US Food and Drug Administration for the validation and commercialization of DNA transfection reagents, RNA transfection reagents, and related technologies is supporting product development, although regulatory standards remain stringent. Asia-Pacific is expected to record the highest compound annual growth rate through 2035. Regional expansion is being supported by growing active pharmaceutical ingredient production, increased outsourcing of biologics manufacturing, and investment in advanced research and production infrastructure. China, Japan, South Korea, and Australia are among the markets expected to contribute to this growth. Competitive Landscape The non-viral transfection reagents market includes established life sciences companies and specialized technology developers. Companies evaluated within the competitive landscape include: <ul><li>BEX</li><li>Bio-Rad Laboratories</li><li>Harvard Bioscience</li><li>LocateBio</li><li>MaxCyte</li><li>MilliporeSigma</li><li>Nepa Gene</li><li>N4 Pharma</li><li>OZ Biosciences</li><li>Thermo Fisher Scientific</li></ul> Competitive positioning is influenced by delivery efficiency, compatible cell types, supported nucleic acid modalities, serum compatibility, product portfolio breadth, and developer capabilities. Strategic partnerships between transfection technology providers and cell and gene therapy developers are expected to remain important as companies seek to improve process scalability and accelerate clinical development. Research Coverage The market report provides revenue forecasts and opportunity analysis by method, application, end-user, and region. It also examines the competitive landscape for non-viral transfection reagents, electroporation-based systems, and other non-viral delivery platforms. Additional coverage includes company profiles, technology benchmarking, potential strategic partners, pharmaceutical industry initiatives, pricing strategy analysis, and market impact assessment. The research also evaluates patents filed or granted in the non-viral transfection systems sector and analyzes more than 450 peer-reviewed scientific publications. Primary research incorporates perspectives from business development executives, scientific leaders, research professionals, product managers, and cell therapy process development specialists across the United States, France, Switzerland, and Chile. Key Attributes <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Report Attribute</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">Details</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">No. of Pages</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">294</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecast Period</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">2026-2035</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Estimated Market Value (USD) in 2026</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$0.89 Billion</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecasted Market Value (USD) by 2035</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$2.01 Billion</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Compound Annual Growth Rate</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">9.5%</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">Regions Covered</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">Global</td></tr></table> A selection of companies mentioned in this report includes, but is not limited to: <ul><li>20Med Therapeutics</li><li>4basebio</li><li>AAT Bioquest</li><li>Aera Therapeutics</li><li>Agilent Technologies</li><li>Altogen Biosystems</li><li>Applied Biological Materials (abm)</li><li>Arbor Biotechnologies</li><li>ATCC</li><li>Avectas</li><li>BEX</li><li>Bio Basic</li><li>Biomaterials USA</li><li>Biontex Laboratories</li><li>BioPact</li><li>Bio-Rad Laboratories</li><li>BIOTOOLS</li><li>Canvax</li><li>Celetrix</li><li>Cell Applications</li><li>CellFE</li><li>Code Biotherapeutics</li><li>Cosmo Bio</li><li>Creative Biolabs</li><li>CyGenica</li><li>Cytiva</li><li>DropGenie</li><li>Drummond Scientific</li><li>ENDOSCAPE</li><li>Enzo Life Sciences</li><li>Etta Biotech</li><li>Exicure</li><li>EZ Biosystems</li><li>FormuMax Scientific</li><li>Fugent</li><li>GeneCopoeia</li><li>GeneDireX</li><li>GenEdit</li><li>Generation Bio</li><li>Genlantis (acquired by AMSbio)</li><li>Gennao Bio</li><li>Genprex</li><li>Harvard Bioscience</li><li>Horizon Discovery</li><li>Ichor Medical Systems</li><li>Icosagen</li><li>Immudicon</li><li>IMUNON</li><li>In-Cell-Art</li><li>Incisive Genetics</li><li>indee labs</li><li>INOVIO Pharmaceuticals</li><li>iNtRON Biotechnology</li><li>InvivoGen</li><li>Kodikaz Therapeutic Solutions</li><li>Kytopen</li><li>Lemonex</li><li>Locate Bio</li><li>Lonza</li><li>MaxCyte</li><li>Mayo Foundation for Medical Education and Research (MFMER)</li><li>MilliporeSigma</li><li>Miltenyi Biotech</li><li>Mirus Bio (acquired by MlliporeSigma)</li><li>N4 Pharma</li><li>NanoEntek</li><li>NAVAN Technologies</li><li>nChroma Bio</li><li>Nepa Gene</li><li>Neuromics</li><li>Ningbo Scientz Biotechnology</li><li>OpenCell Technologies</li><li>OrganoLinX</li><li>OriGene Technologies</li><li>OZ Biosciences</li><li>Polyplus (acquired by Sartorius)</li><li>Polysciences</li><li>Precision Bio Laboratories</li><li>Promega</li><li>QIAGEN</li><li>RJH Biosciences</li><li>Roche</li><li>Santa Cruz Biotechnology</li><li>ScreenFect</li><li>SignaGen Laboratories</li><li>Sino Biological</li><li>St. Jude Medical</li><li>Sutter Instrument</li><li>Synvolux</li><li>System Biosciences</li><li>Takara Bio</li><li>Tecrea</li><li>Thermo Fisher Scientific</li><li>T-Pro Biotechnology</li><li>Tritech Research</li><li>Tritech Research</li><li>Tyris Tx</li><li>University of Texas</li><li>Westburg Life Sciences</li><li>Yeasen Biotechnology</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/5749416/non-viral-transfection-reagents-market-3rd?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=32m7c6&amp;utm_campaign=2324451+-+Non-Viral+Transfection+Reagents+Market+Report+(3rd+Edition)+by+Type+of+Non-Viral+Transfection+Method%2c+Application+Area%2c+End-User+%26+Region%2c+Featuring+Bio-Rad%2c+MaxCyte%2c+MilliporeSigma%2c+Thermo+Fisher+Scientific&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/ehlowk</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/NTk5ZDQ1ZTQtZTcwYS00M2I3LThhYWQtOTczOGViOTQzNjM0LTEwMjY3MzctMjAyNi0wOC0xMS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn